Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…
News
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in…
Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in the journal…
The Pulmonary Fibrosis Foundation (PFF) recently announced that it has acquired the Daughters of Pulmonary Fibrosis program from the Coalition for Pulmonary Fibrosis (CPF), a 501c(3) nonprofit organization based in California that serves the pulmonary fibrosis (PF) community. By assuming the administration of the Daughters of PF program and giving money raised…
miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the start of a Phase 1 clinical trial on the company’s product MRG-201 developed as a therapy for fibrotic conditions. MicroRNAs (miRNAs) are small RNAs that act as master regulators of…
aTyr Pharma Inc., a biotherapeutics company that discovers and develops medicines through its Physiocrine platform for the treatment of rare diseases, has announced the selection of a new Investigational New Drug (IND) candidate, an iMod.Fc molecule. The selected therapeutic molecule aims to aid in the management of severe fibrotic…
Veracyte, Inc.recently presented four abstracts on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel in Washington, D.C., in…
Boehringer Ingelheim recently announced new positive data on the company’s FDA-approved therapy OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). The results were presented at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washington, D.C. OFEV is a tyrosine-kinase inhibitor (TKI) that targets growth factors, such as the vascular endothelial…
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure in the…
Genentech, a member of the Roche Group, recently presented two abstracts on the company’s product Esbriet (pirfenidone), an oral drug developed for the treatment of pulmonary fibrosis (PF), at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada. Both abstracts were…
